PolymarketVerificar disponibilidadeSem KYCDados de resolução verificadosBem calibradoProbabilidade implícita atual
December 31, 67%Líder entre 3 opções
December 31, 67%Qualidade do mercado
63 / 100
Qualidade médiaVolume 24h
276,1 €
Liquidez
19,1 mil €
Liquidez médiaSpread
1.0 pt
Spread apertadoComentários
0
Dados do mercado
Atualizado há 15 minutos
19/08/26, 17:49 UTC1/01/28, 04:59 UTC
Tendências
Condições da plataforma
Fonte: Polymarket
Estas condições são informativas; as operações simuladas da CoinRithm seguem regras próprias.
- Ordem mínima (cotas):
- 5
- Incremento de preço:
- 1 pontos percentuais
- Taxas:
- Sim
Mercados Relacionados
Perguntas relacionadas para dar contexto, não uma comparação de contratos equivalentes.
Is Rosie the dog's AI-designed mRNA cancer vaccine legitimate?
Manifold MarketsIs Rosie the dog's AI-designed mRNA cancer vaccine legitimate?
Manifold MarketsSkin cancer vaccine BLA submitted by which date?
PolymarketWill the Russian cancer vaccine work?
Manifold MarketsFDA approves Retatrutide this year?
PolymarketFDA approves YCT-529 male birth control pill before 2035?
Manifold MarketsRegras
This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants approval of intismeran autogene for any indication by December 31, 2027, 11:59 PM ET.
- Otherwise, this market will resolve to "No".
- Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program.
- Differences in neoantigen composition between patients will not affect resolution.
- Changes to the product's formulation will not affect resolution, provided the FDA approves the product described above.
- Approval as part of a combination regimen will qualify.
